Ilaprazole
As of the edition of 20 October 2026, Ilaprazole is a small molecule: in active development; acts on ATP4A and ATP4B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 24, 0 stopped early
- Disease areas
- Digestive system; Infections; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 0 |
| Phase 3 | 8 | 7 | 1 | 0 |
| Phase 4 | 7 | 6 | 0 | 0 |
| All trials | 24 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Livzon Pharmaceutical | Lead sponsor of trials | 2004 to now |
| Il-Yang Pharm | Lead sponsor of trials | 2005 to now |
| Takeda | Lead sponsor of trials | 2007 to now |